Scott Joseph Antonia
Medical Oncology
Credentials: · ·
History
Research
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
New England Journal of Medicine · 2012 · 10,404 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 7,953 citations
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 7,024 citations
36 papers
35 papers
32 papers
27 papers · 3 as a fellow
- DS
20 papers
20 papers
20 papers
20 papers
Grants
- 1997–2029
Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $780.9K · Duke University
- 2022–2027
Novel Roles of PCSK9 in Regulating the Tumor Immune Microenvironment During Radiotherapy
National Cancer Institute · R01
PI · $2.1M · Duke University
- 2018–2023
Eco-Evolutionary Dynamics of NSCLC to Immunotherapy: Response and Resistance
National Cancer Institute · U01
PI · $3.3M · h. Lee Moffitt Cancer Ctr & Res Inst
- 2016–2019
Targeting the Adenosine A2A Receptor Immune Checkpoint in Lung Cancer Patients
National Cancer Institute · R01
Contact PI · $959.7K · h. Lee Moffitt Cancer Ctr & Res Inst
Clinical trials
- 2026–2029
C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy
Principal investigator · Not yet recruiting · Phase 2
AbelZeta Inc.
- 2026–2030
C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease
Principal investigator · Withdrawn · Phase 1, Phase 2
AbelZeta Inc.
- 2022–2024
Principal investigator · Terminated · Phase 2
Eziafa Oduah, MD, PhD, MPH
- 2007–2019
Principal investigator · Completed · Phase 2
H. Lee Moffitt Cancer Center and Research Institute